Where the T2D AID market is open — scored opportunity density across hardware-software UX, ecosystem, AI, and access.
The T2D AID market has a critical gap in 'ecosystem convergence' — specifically integrated sensor-hardware bundles and native smartphone control. As incumbents consolidate the market through pharmacy-channel access and simplified AI algorithms, the opportunity is to push deep technical integrations with CGM leaders and transition away from standalone controllers to remain a viable acquisition target for pharma giants like Sanofi or Lilly.
Eliminate the handheld PDM in favor of a native smartphone app that controls bolusing and settings.
Modern T2D patients demand 'discreet' management. Insulet and Tandem have already moved to phone-only control, making standalone controllers obsolete.
Ability to push software updates to the pump hardware remotely to add features or improve algorithms without replacing the device.
As AI algorithms improve, patients expect their hardware to evolve. Competitors use this to extend product lifecycles.
Direct commercial and technical integration that allows the pump to receive glucose data directly without requiring a phone as a bridge.
The 'Consolidation of AID Ecosystem' trend shows that standalone hardware is failing; integration with Dexcom and Senseonics is now the market floor.
API-based data sharing that automatically pushes delivery data into physician-facing platforms used for billing and RPM.
Providers managing T2D populations rely on Glooko and RPM platforms for workflow efficiency; manual data uploads are a significant barrier to adoption.
A 'decision-free' system where the patient only enters their body weight and the AI handles all dosing without carb counting or periodic basal adjustments.
T2D patients often have lower tech-literacy or clinical support than T1 patients; Beta Bionics' simplified 'Bionic Pancreas' approach is the primary competitor for this segment.
Integration of behavioral health nudges and exercise data to adjust insulin sensitivity factors in real-time using ML.
T2D patients are highly lifestyle-dependent. Integrating data from partners like One Drop to adjust for meals/exercise is a major differentiator.
A 'pay-as-you-go' model through the pharmacy channel (Tier 2/3) rather than the expensive Durable Medical Equipment (DME) channel.
Insulet's success in T2D is driven by ease of access. T2 patients are more price-sensitive and prefer pharmacy-benefit over high-deductible DME.